PIK3CA and cancer: For example, PIK3CA mutations predicted to disable interfaces with regulator N-terminal SH2 domains (above) have a statistical significant cross-cancer lower survival and higher hazard ratio (Cox, p = 1.3e−2; Table S5b,c) than those predicted to affect the C-terminal SH2 domains.